Abstract: Methods, systems, and devices for wireless communications are disclosed by the present application. A request to establish a call using a first connection may be received, the first connection using a first radio access technology to communicate with a radio access network. During execution of a procedure to establish the call, a command to handover communications from the first connection to a second connection that uses a second radio access technology to communicate with the radio access network may be received. The second connection may be established in response to the command, and a message indicating that the request to establish the call was successfully received may be transmitted over the second connection. Also, a message indicating that an alert of the call is being issued may be transmitted over the second connection.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, via a first connection of a dual connectivity mode, a first packet having a first sequence number. The UE may receive, via a second connection of the dual connectivity mode, a second packet having a second sequence number. The UE may determine, based at least in part on the first sequence number and the second sequence number, that the first packet is received out of order. The UE may maintain a packet order for reception of subsequent packets via the first connection or the second connection. The UE may drop the first packet based at least in part on the determination that the first packet is received out of order. Numerous other aspects are provided.

Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may communicate with a base station according to a first radio access technology (RAT) in a first frequency range. The UE may perform measurements on a set of candidate cells of a second RAT or a second frequency range based on a determination for the UE to operate according to the second RAT or the second frequency range. The UE may perform a mobility procedure to establish a connection with a first cell of the set of candidate cells based on a determination that a first value of a first measurement parameter for the first cell satisfies a first threshold, and further based on a comparison of a different, second value of a second measurement parameter for the first cell to a second threshold.

Abstract: The present invention relates to a novel tumor-specific polypeptide and use thereof. In particular, the present invention relates to a tumor-specific polypeptide having high affinity for HLA-A0201 and having cytotoxic T lymphocyte inducing ability, and its use for diagnosing, preventing and treating diseases (especially cancer) associated with high expression of the TWISTNB gene or mutation(s) in the TWISTNB gene.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from a base station associated with a first radio access technology (RAT), a neighbor cell list including entries for at least a first set of neighbor cells and a second set of neighbor cells, the first set of neighbor cells and the second set of neighbor cells associated with a second RAT. The UE may determine that the first set of neighbor cells is associated with a first network operator and that the second set of neighbor cells is associated with a second network operator. The UE may measure at least one neighbor cell of the neighbor cell list based at least in part on prioritization of the first set of neighbor cells relative to the second set of neighbor cells. Numerous other aspects are described.

Abstract: A method for activating an adaptive immune response by adding allogeneic dendritic cells (DCs) and/or viral antigen peptides to conventional DC vaccines to expand the DC vaccine antigen spectrum with the aid of exogenous DC effect, thereby enhancing the anti-tumor effect of the DC vaccine.

Abstract: A user equipment (UE) receives a SIB1 message from a base station. The SIB1 message lists first and second public land mobile network identifiers (PLMN IDs), the first PLMN ID having a corresponding tracking area code (TAC) and the second PLMN ID not having a TAC. The UE reports the first PLMN ID and TAC but not the second PLMN ID while performing PLMN selection. In another aspect, the UE unsuccessfully attempts to select or reselect to a shared cell of the base station with the second PLMN ID. In response to the failed attempt, the UE bars the shared cell as a candidate for cell selection/reselection, due to a missing TAC. When the UE attempts to select or reselect to the shared cell with the first PLMN ID, which may or may not have a TAC, the UE reevaluates the barring due to selection of the first PLMN ID.

Abstract: Embodiments include systems and methods for wireless device signaling a network regarding customized ringing signal (CRS) capability and use of such information by the network. Various embodiments may receiving from the network an INVITE message notifying the wireless device of an incoming call, determining whether the INVITE message indicates that the network provides CRS service if the wireless device supports a CRS function, and including an indication in a response to the INVITE that the wireless device supports the CRS function in response to determining that the INVITE message includes an alert information header field indicating that the network provides CRS service. Various embodiments include a network computing device receiving such information and performing negotiations for CRS service with the wireless device only if the wireless device indicates CRS functional capability.

Abstract: Provided are a tumour antigen polypeptide having the amino acid sequence as shown in SEQ ID NO: 2 or a variant thereof; a nucleic acid encoding same; a nucleic acid construct, an expression vector, and a host cell comprising the encoding nucleic acid; and an antigen presenting cell presenting the tumour antigen polypeptide on the cell surface and an immune effector cell thereof. Also provided is the use of the polypeptide, nucleic acid, antigen presenting cell or immune effector cell in the diagnosis, prevention and treatment of cancers.

Abstract: Provided are a tumor antigen polypeptide having the amino acid sequence as shown in SEQ ID NO: 2 or a variant thereof; a nucleic acid encoding the same; a nucleic acid construct, an expression vector, and a host cell containing the encoding nucleic acid; and an antigen presenting cell presenting the tumor antigen polypeptide on the cell surface and an immune effector cell thereof. Also provided is the use of the polypeptide, nucleic acid, antigen presenting cell or immune effector cell in the diagnosis, prevention and treatment of cancers.

Abstract: Disclosed are systems and methods of label-free detecting cellular physiological activities involving monitoring local refractive index changes associated with cellular physiological activities using a single ultracompact light emitting diode (LED) chip serving as a refractometer.

Abstract: Provided is a MART-1 (27-35) epitope-specific T cell receptor, comprising an ? chain and a ? chain. The ? chain comprises three complementary determining regions, respective sequences thereof being positions 61-66, positions 84-89, and positions 124-136 of SEQ ID No. 3. The ? chain comprises three complementary determining regions, respective amino acid sequences thereof being positions 46-50, positions 68-73, and positions 112-125 of SEQ ID No. 4. A T cell expressing the TCR can effectively recognize a MART-1 (27-35) epitope polypeptide supported on a T2 cell and secrete IFN-?, thereby demonstrating the functionality of the receptor. Use of the TCR with a relevant drug target allows for effective drug development.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.

Abstract: The present invention relates to a novel tumor-specific polypeptide and use thereof. In particular, the present invention relates to a tumor-specific polypeptide having high affinity for HLA-A0201 and having cytotoxic T lymphocyte inducing ability, and its use for diagnosing, preventing and treating diseases (especially cancer) associated with high expression of the TWISTNB gene or mutation(s) in the TWISTNB gene.

Abstract: Provided are a polypeptide and nucleic acid for encoding the polypeptide, a nucleic-acid construct, an expression vector, and a host cell containing the nucleic acid, an antigen-presenting cell presenting the polypeptide on the surface of the cell, and immune effector cell thereof, a pharmaceutical composition containing the polypeptide, a vaccine containing the nucleic acid, the nucleic acid construct, the expression vector, the host cell, the antigen-presenting cell, and the immune effector cell, and an antibody recognizing the polypeptide. Also provided is a therapeutic method using the polypeptide, the nucleic acid, the pharmaceutical composition, the vaccine, and the antibody. Also provided are a diagnosis method and diagnosis apparatus for detecting the described polypeptide. Also provided is an application of the polypeptide in preparing a vaccine, a tumor diagnosis kit, or a pharmaceutical composition, and an application of the polypeptide or the nucleic acid as a test target in tumor diagnosis.